Scholarlink

<p>We previously showed the feasibility and immunologic effects of multivalent peri-lymphatic cytokine injection (IRX-2) in early-stage breast cancer. We now report outcomes of a pilot evaluation of IRX-2 + pembrolizumab induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer (TNBC). Single-cycle induction was associated with radiographic tumor regression, tumor necrosis, immune infiltration, and high pathologic complete response rate following platinum-sparing chemo-immunotherapy. Further investigation of peri-lymphatic cytokines in TNBC is warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月17日

查看全文
  • Alan Su,
  • Erin C. Hong,
  • Nicole Moxon,
  • Staci L. Mellinger,
  • Tracy Kelly,
  • Alison K. Conlin,
  • Zheng Zhu Topp,
  • Philippa Newell,
  • Nicole Fredrich,
  • Kristen P. Massimino,
  • Yaping Wu,
  • Maritza Martel,
  • William L. Redmond,
  • Shaghayegh Aliabadi-Wahle,
  • Zhaoyu Sun,
  • James Imatani,
  • Sasha E. Stanton,
  • Douglas A. Hanes,
  • Michael Simanonok,
  • Wesley Rosales,
  • Tyler J. Nielsen,
  • David B. Page

摘要

We previously showed the feasibility and immunologic effects of multivalent peri-lymphatic cytokine injection (IRX-2) in early-stage breast cancer. We now report outcomes of a pilot evaluation of IRX-2 + pembrolizumab induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer (TNBC). Single-cycle induction was associated with radiographic tumor regression, tumor necrosis, immune infiltration, and high pathologic complete response rate following platinum-sparing chemo-immunotherapy. Further investigation of peri-lymphatic cytokines in TNBC is warranted.